Related Experiment Video
Updated: Aug 4, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
Arvind Ravi1,2, Matthew D Hellmann3, Monica B Arniella1
1Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Abstract:
Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features underlying response to checkpoint inhibitors in NSCLC, we describe here the first joint analysis of the Stand Up To Cancer-Mark Foundation cohort, a resource of whole exome and/or RNA sequencing from 393 patients with NSCLC treated with anti-PD-(L)1 therapy, along with matched clinical response annotation. We identify a number of associations between molecular features and outcome, including (1) favorable (for example, ATM altered) and unfavorable (for example, TERT amplified) genomic subgroups, (2) a prominent association between expression of inducible components of the immunoproteasome and response and (3) a dedifferentiated tumor-intrinsic subtype with enhanced response to checkpoint blockade. Taken together, results from this cohort demonstrate the complexity of biological determinants underlying immunotherapy outcomes and reinforce the discovery potential of integrative analysis within large, well-curated, cancer-specific cohorts.
Insights
This study analyzed molecular features in 393 non-small cell lung cancer (NSCLC) patients treated with anti-PD-(L)1 therapy. Key findings reveal genomic subgroups, immunoproteasome expression, and a dedifferentiated subtype associated with immunotherapy response.
Area of Science:
- Oncology
- Immunotherapy
- Genomics
Background:
- Anti-PD-1/PD-L1 agents have revolutionized advanced non-small cell lung cancer (NSCLC) treatment.
- Understanding molecular predictors of response to immune checkpoint inhibitors is crucial for optimizing therapy.
Purpose of the Study:
- To conduct the first joint analysis of molecular features and clinical response in a large NSCLC cohort treated with anti-PD-(L)1 therapy.
- To identify genomic, transcriptomic, and subtype-specific associations with treatment outcomes.
Main Methods:
- Whole exome and/or RNA sequencing of 393 NSCLC patients treated with anti-PD-(L)1 therapy.
- Integration of molecular data with matched clinical response annotations.
- Analysis of genomic alterations, gene expression, and tumor subtypes.
Main Results:
- Identified favorable (e.g., ATM altered) and unfavorable (e.g., TERT amplified) genomic subgroups.
- Demonstrated a strong association between inducible immunoproteasome component expression and response.
- Discovered a dedifferentiated tumor-intrinsic subtype with enhanced response to checkpoint blockade.
Conclusions:
- Molecular features, including specific genomic alterations, immunoproteasome activity, and tumor subtypes, significantly influence anti-PD-(L)1 therapy outcomes in NSCLC.
- Integrative analysis of large, well-curated cohorts is essential for uncovering complex biological determinants of immunotherapy response.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
11:44Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019